- Commonly prescribed drugs affect decisions to harm oneself and others
- Research reveals how the human brain might reconstruct past events
- Research into genetic influences on epilepsy and migraines
- Fast forwarding treatment for neurodegenerative disorders at LWENC
- Natural genetic variation gives complete resistance in prion diseases
- Professor Lees awarded ABN Medal 2015
- Professor Hardy elected member of EMBO
- Working with Saracens to monitor concussion in rugby
- Mutations in two novel genes cause primary dystonia
- A new genetic switch uncovered in the long genes expressed in our brain
- Professor Alan Thompson elected to the Fellowship of the Academy of Medical Sciences
- UCL Institute of Neurology researchers awarded MRC fellowships
- Professor Ray Dolan has been elected Member of the European Academy of Sciences and Arts
- Deep brain stimulation for Tourette syndrome
- Behaviour changes common in early stage familial Alzheimer's
- Imaging shows early brain changes in FTD patients
- New test measures deadly protein in Huntington’s disease patients’ spinal fluid
- Professor Mary Reilly is elected to be the first female President of the Association of British Neurologists in 83 years
- Structure of genetic messenger molecules reveals key role in diseases
- Professor Nick Fox speaks about trial in early onset familial Alzheimer's disease at UCL
- First major exhibition to explore BSE and its impact opens at Hayward Gallery
- Government pledges £300m for dementia research
- UCL awarded £10m to develop new dementia treatments
- BRC awards £700,000 to neuroscience projects
- UCL Neuroscience rated top by research strength in the REF2014
- $5.9 million boost for SUDEP research
- Secret of tetanus toxicity offers new way to treat motor neuron disease
- Harm to others outweighs harm to self in moral decision making
- Auto anomaly detection for brain imaging awarded £1m grant
- Spinal surgery: OECs studies to start in 2015
- New brain tumour research Centre of Excellence is unveiled
- UCL awarded £13.5 million to advance medical research facilities
- UCL research helps paralysed man to recover function
- Stenting safe and effective for long-term stroke prevention
- Department of Clinical & Experimental Epilepsy re-designated as a WHO Collaborating Centre
- Leonard Wolfson Experimental Neurology Centre open evening
- Brain stimulation to improve cognition in dementia
- Professor Lees receives Jay Van Andel Award for Outstanding Research in Parkinson’s Disease
- Creating brain cells from skin to study Alzheimer's
- Queen Square authors prominent in Brain collection of classic articles
- Toxic proteins implicated in frontotemporal dementia and motor neurone disease
- GCH1 gene and Parkinson’s risk
- Double mutation linked to frontotemporal dementia
- Equation to predict happiness
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia
- Researchers test whether diabetes drug can help Parkinson’s patients
- Acute optic neuritis: a review and proposed protocol
- Hippocampal subfield size predicts the precision of memory recall
- Immune system implicated in dementia development
- UCL and Chiesi Group announce partnership to develop a novel therapeutic for birth asphyxia
- Professor Golay made a Fellow of the ISMRM
- The new Leonard Wolfson Experimental Neurology Centre (LWENC) has opened for clinical studies and trials
- Professor Rees wins UCLU Student Choice Teaching Award
- New epilepsy treatment offers ‘on demand’ seizure suppression
- Professor Tabrizi and Professor Price elected to Fellowship of the Academy of Medical Sciences.
- Professor Dolan and Professor Friston elected to EMBO membership
- Vitamin B3 treatment for ataxia shows promise in first human trial
- Teaching Awards 2014
- Light-activated neurons from stem cells restore function to paralysed muscles
- UCL and Max Planck Society invest €5m to open world’s first computational psychiatry centre
- Successful launch of new annual leading edge neurology course
- Statins could help control MS
- Professor Hardy awarded Thudichum Medal by Biochemical Society
- Population Screening for vCJD Using a Novel Blood Test
- Chief Medical Officer appoints Professor Rossor as NIHR National Director for Dementia Research
- New partnership between UCLP brain tumour scientists and Brain Tumour Research
- Professor Hardy awarded Dan David Prize for work on the amyloid gene encoding APP
- NIHR award £650,000 for research into rare neurodegenerative and neuromuscular diseases
- Lowering levels of toxic protein reverses abnormalities in cells from patients with Huntington's disease
- Teaching Awards 2015
NIHR award £650,000 for research into rare neurodegenerative and neuromuscular diseases
21 February 2014
The National Institute of Health Research (NIHR) Rare Diseases Translational Research Collaboration has awarded a total of £650,000 to extend research into rare neurodegenerative and neuromuscular diseases.
One of the awards was made to the rare neuromuscular theme which is led by Professor Michael Hanna, Director of UCL’s Institute of Neurology, where research projects into Duchenne Muscular Dystrophy (DMD) and inclusion body myositis (IBM) have been funded.
Professor Francesco Muntoni, supported by the Great Ormond Street BRC, will study groups of patients with DMD and measure their particular genetic defects more precisely.
Professor Hanna said: “The DMD programme is going to collect large cohorts nationally through the BRC infrastructure to study their natural history and their genetics accurately. We aim to understand the variation in disease severity and assess variations in treatment response in therapeutic trials."
This will be a valuable step in the translational pathway for DMD patients.
Professor Michael Hanna
The second study will explore IBM, an inflammatory muscle disease depicted by progressive weakness and wasting of both distal and proximal muscles. Professor Hanna explained how BRC work on stratification of patients based on muscle biopsy appearances, clinical assessment and MRI evaluation will be valuable in designing and involving patients in clinical trials.
Based on the BRC’s strong links with industry it is highly likely trials of two new agents will be able to start in the next couple of years.
Professor Michael Hanna
Under the other award Professor Nick Wood, Director of the BRC Neurosciences programme, will investigate the C9orf72 gene. People with the C9orf72 mutation are at an increased risk of developing amyotrophic lateral sclerosis, or of developing frontotemporal dementia.
Professor Wood and his team, made up of a consortium of BRCs including Kings College, led by Professor Chris Shaw and Oxford, led by Professor Kevin Talbot, will study people with known mutations of the C9orf72 gene to allow for in-depth phenotype analyses.
Professor Wood said: “Rather than define phenotypes and chase down genes, we have taken the other route. We will study patients and their families with known mutations, permitting a whole range of complex phenotype questions from a simpler genetic background to be addressed”.
In addition, Professor Wood will develop research into the LRRK2 gene (the greatest known genetic contributor to Parkinson’s disease). This will be led by Professor Wood and Professor Huw Morris, from the UCL Institute of Neurology, and involve input from Kings College and Oxford BRCs.
We hope to find, in much more detail, the range of phenotypes from a particular mutation which will guide clinical practice in particular diagnosis.
Professor Nick Wood
Page last modified on 07 feb 14 17:24